JP2023507729A - 腫瘍抗原を標的とするｍａｎａボディおよび使用方法 - Google Patents

腫瘍抗原を標的とするｍａｎａボディおよび使用方法 Download PDF

Info

Publication number
JP2023507729A
JP2023507729A JP2022536937A JP2022536937A JP2023507729A JP 2023507729 A JP2023507729 A JP 2023507729A JP 2022536937 A JP2022536937 A JP 2022536937A JP 2022536937 A JP2022536937 A JP 2022536937A JP 2023507729 A JP2023507729 A JP 2023507729A
Authority
JP
Japan
Prior art keywords
seq
cells
hla
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022536937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507729A5 (https=
Inventor
バート フォーゲルシュタイン
ケネス ダブリュ． キンズラー
エミリー ハン－チュン シュエ
ジャクリン ダグラス
マイケル エス． フアン
アレクサンダー エイチ． パールマン
ニコラス パパドプロス
シビン ゾウ
ブライアン ジェイ． モグ
キャサリン エム． ライト
サンドラ ビー． ギャベリ
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2023507729A publication Critical patent/JP2023507729A/ja
Publication of JP2023507729A5 publication Critical patent/JP2023507729A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022536937A 2019-12-17 2020-12-17 腫瘍抗原を標的とするｍａｎａボディおよび使用方法 Pending JP2023507729A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949220P 2019-12-17 2019-12-17
US62/949,220 2019-12-17
US202063059638P 2020-07-31 2020-07-31
US63/059,638 2020-07-31
PCT/US2020/065617 WO2021127184A1 (en) 2019-12-17 2020-12-17 MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

Publications (2)

Publication Number Publication Date
JP2023507729A true JP2023507729A (ja) 2023-02-27
JP2023507729A5 JP2023507729A5 (https=) 2023-12-22

Family

ID=76478564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536937A Pending JP2023507729A (ja) 2019-12-17 2020-12-17 腫瘍抗原を標的とするｍａｎａボディおよび使用方法

Country Status (7)

Country Link
US (1) US20230051847A1 (https=)
EP (1) EP4077370A4 (https=)
JP (1) JP2023507729A (https=)
CN (1) CN115210255A (https=)
AU (1) AU2020407591A1 (https=)
CA (1) CA3164446A1 (https=)
WO (1) WO2021127184A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269370B2 (en) 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
IL313491A (en) * 2021-12-16 2024-08-01 Univ Johns Hopkins Managbodies directed to P53 tumor antigens and methods of use
IL318933A (en) * 2022-08-18 2025-04-01 Immunocore Ltd Multi-functional binding molecules
EP4474016A1 (en) * 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
AU2024325783A1 (en) * 2023-08-11 2026-02-26 Kelonia Therapeutics, Inc. Compositions for modifying cells
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025217204A1 (en) * 2024-04-08 2025-10-16 The Johns Hopkins University Methods and materials for treating p53+ cancers
EP4659812A1 (en) * 2024-06-07 2025-12-10 Bumm, Thomas Detection methods and combination therapies of cells with extracellular ras expression
CN119498254B (zh) * 2024-12-06 2025-10-24 北京肿瘤医院(北京大学肿瘤医院) 小鼠胃癌自发瘤模型的构建方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154246A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
WO2018213467A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
WO2019164451A1 (en) * 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
CN108250301A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
EP3599250A4 (en) * 2017-01-24 2021-06-09 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. ANTIBODY CONJUGATE AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
SG11202002635RA (en) * 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154246A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
WO2018213467A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
WO2019164451A1 (en) * 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas

Also Published As

Publication number Publication date
WO2021127184A1 (en) 2021-06-24
CN115210255A (zh) 2022-10-18
EP4077370A1 (en) 2022-10-26
EP4077370A4 (en) 2024-02-28
CA3164446A1 (en) 2021-06-24
US20230051847A1 (en) 2023-02-16
AU2020407591A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP2023507729A (ja) 腫瘍抗原を標的とするｍａｎａボディおよび使用方法
JP7513605B2 (ja) 新規な抗体ならびにそれを調製および使用するための方法
CN113825771B (zh) 针对密蛋白18a2的抗体及其应用
US12129296B2 (en) Anti-human claudin 18.2 monoclonal antibody and application thereof
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
JP6925421B2 (ja) プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途
CN104271602B (zh) 双特异性抗体
US20240360239A1 (en) Therapeutic Anti-CD9 Antibody
JP2015524390A (ja) Ｄｌｌ４に特異的に結合する新規モノクローナル抗体及びその用途
AU2018269370A1 (en) Manabodies and methods of using
JP2021528382A (ja) 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
AU2017306506A1 (en) Antibody to programmed cell death 1 (PD-1) and use thereof
US12516133B2 (en) TGFβ/PD-L1 bispecific binding proteins
EP3655026A2 (en) Antigen binding regions against fibronectin type iii domains and methods of using the same
Hsiue TARGETING SHARED CANCER NEOANTIGENS WITH BISPECIFIC T CELL-RETARGETING ANTIBODIES
RU2811431C2 (ru) Антитело против клаудина 18a2 и его применение
TW202545991A (zh) 抗ｃｄ２８抗體及其用途
Skoraa et al. Generation of MANAbodies against KRAS G12V-A2 and EGFR L858R-A3
HK40095347A (zh) 上皮钙黏素特异性抗体
HK40062048B (zh) 针对密蛋白18a2的抗体及其应用
HK40062048A (en) Antibody against claudin 18a2 and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260420